In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Buys Eyetech, Market Rubs Eyes

Executive Summary

Not the most obvious of biotech-biotech combinations. OSI thinks it can make money from Eyetech's lone product pegaptanib (Macugen), a breakthrough new treatment for age-related macular degeneration. The market has reacted poorly to the deal, worried that Macugen will be made obsolete by Genentech's Lucentis, due to be launched in late 2006.
Advertisement

Related Content

Ophthotech Corp.
Archemix Reduces Aperture to Pursue Orphan Diseases
Archemix Reduces Aperture to Pursue Orphan Diseases
Ophthotech Raises $36 million, In-licenses Aptamers
Bayer/Regeneron: Typically Rich, Extra Regional
Bayer/Regeneron: Typically Rich, Extra Regional
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
Spotting Switching Opportunities in Ophthalmology
Flying Through FDA: Test Runs For Pilot 1
Novartis Opens Door to Broad Dealmaking in RNAi

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel